

[Emtricitabine](#)

Not recommended as an essential medicine

Section:

[6. Anti-infective medicines 6.4. Antiviral medicines 6.4.2. Antiretrovirals 6.4.2.1. Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors](#)

ATC codes: [J05AF09](#)

EMLc

Indication

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

ICD11 code: [1C62.Z](#)

INN

Emtricitabine

Medicine type

Chemical agent

List type

Core

Additional notes

Emtricitabine (FTC) is an acceptable alternative to lamivudine (3TC), based on knowledge of the pharmacology, the resistance patterns and clinical trials of antiretrovirals.

Formulations

Oral > Liquid: 10 mg per mL

Oral > Solid: 200 mg

EML status history

First added in 2007 ([TRS 946](#))

Changed in 2007 ([TRS 950](#))

Removed in 2015 ([TRS 994](#))

Sex

All

Age

Also recommended for children

Age restriction

>3 months

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Emtricitabine](#)

DrugBank

[Emtricitabine](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the removal of emtricitabine from the EML and EMLc on the basis that listing is not aligned with dosing guidelines in the 2013 WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (1), and also because of the availability of fixed-dose combination formulations containing emtricitabine. References: 1. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. Available from: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.